Pretreatment NRS-2002 scores combined with hematologic inflammation markers are independent prognostic factors in patients with resectable thoracic esophageal squamous cell carcinoma

Xin-Wei Guo1,*, Yang-Chen Liu2,*, Fei Gao2,*, Sheng-Jun Ji3, Ju-Ying Zhou1, Lei Ji1, Shao-Bing Zhou2

1Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 2Department of Radiation Oncology, Affiliated Taixing People’s Hospital of Yangzhou University, Taixing, People’s Republic of China; 3Department of Radiotherapy and Oncology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, People’s Republic of China

*These authors contributed equally to this work

Background: The purpose of this study was to investigate the prognostic values of Nutritional Risk Screening 2002 (NRS-2002) and hematologic inflammation markers in patients with esophageal squamous cell carcinoma (ESCC) receiving curative esophagectomy.

Materials and methods: A total of 277 patients with ESCC treated with standard curative esophagectomy were retrospectively analyzed. These patients were grouped for further analysis according to the systemic inflammation score (SIS), the combination of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (CNP) score and NRS-2002 score. The Kaplan–Meier method and log-rank test were adopted to calculate and compare the progression-free survival (PFS) and overall survival (OS) rates with these parameters. The Cox proportional hazards model was used to carry out univariate and multivariate analyses. Receiver operating characteristic (ROC) curves were applied to verify the accuracy of SIS, CNP and NRS-2002 for survival prediction.

Results: In univariate analysis, the following factors were significantly associated with poor PFS and OS: sex, T stage, N stage, TNM stage, SIS, CNP and NRS-2002 (all \( P < 0.05 \)). Furthermore, multivariate Cox regression analysis showed that CNP (hazard ratio [HR] = 1.602; 95% confidence interval [CI] 1.341–1.913; \( P = 0.000 \)), NRS-2002 (HR = 2.062; 95% CI 1.523–2.792; \( P = 0.000 \)) and TNM stage (HR = 1.194; 95% CI 1.058–1.565; \( P = 0.048 \)) were independent prognostic factors for PFS. Correspondingly, CNP (HR = 1.707; 95% CI 1.405–2.074; \( P = 0.000 \)), NRS-2002 (HR = 2.716; 95% CI 1.972–3.470; \( P = 0.000 \)) and TNM stage (HR = 1.363; 95% CI 1.086–1.691; \( P = 0.036 \)) were also independent prognostic factors for OS. Finally, the results of ROC curves indicated that CNP and NRS-2002 were superior to SIS as a predictive factor for PFS or OS in patients with ESCC receiving surgery.

Conclusion: This study demonstrated that CNP combined with NRS-2002 is promising as a predictive marker for predicting clinical outcomes in patients with ESCC receiving surgery.

Keywords: esophageal squamous cell carcinoma, surgery, hematological markers, nutritional risk screening, prognosis

Introduction

Esophageal cancer (EC) is the eighth most common malignancy and the fifth most common cause of cancer death all over the world.1 People’s Republic of China accounts for about half of the world’s total cases of EC,2 and esophageal squamous cell carci-
noma (ESCC) is the most lethal pathological type. Despite significant improvements in the diagnosis and treatment, the prognosis of ESCC is still poor due to its aggressive biological behavior. At present, surgical resection remains the best curative method for non-metastatic EC patients. Nevertheless, most of the patients still develop local relapse or distant metastasis after esophagectomy, and so the 5-year overall survival (OS) rate is still unfavorable and ranges from 26.2% to 49.4%. Therefore, it is critical to search some biomarkers for distinguishing patients who are likely to develop recurrence following surgery from patients who are not easy to relapse.

Recently, there is increasing evidence that the survival of cancer patients is determined not only by tumor itself, but also by host-related factors, such as the preoperative nutritional and inflammatory status. Essentially, EC patients have a high risk of being malnourished prior to treatment, and there is accumulating evidence demonstrating that poor nutritional status is associated with inferior clinical prognosis in patients who underwent esophagectomy. Therefore, pretreatment nutritional condition is important for the prognosis of ESCC in patients receiving surgery. At present, there are many assessment methods applied to nutritional evaluation, among these, Nutritional Risk Screening 2002 (NRS-2002) was a new evaluation system, published by the European Society for Clinical Nutrition and Metabolism (ESPEN) in 2002 and was based on 128 randomized controlled trials. It was the first system in the world that was developed via evidence-based medicine with a great advantage of predicting malnutrition risk, especially in patients with carcinoma. Chen et al found that the standard of the NRS-2002 was feasible in China.

In addition, there are several studies demonstrating that the presence of a systemic inflammatory response and malnutrition were associated with a worse prognosis in various malignancies, and the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte–monocyte ratio (LMR) have been studied in EC. Recently, systemic inflammation score (SIS), a novel prognostic score consisting of serum albumin and LMR, and CNP (the combination of NLR and PLR) may be better predictive factors for postoperative clinical outcome in malignancies. To the best of our knowledge, SIS and CNP have been well documented in other types of human malignancies, including EC, but the combination of nutritional status and hematological markers has rarely been studied in ESCC patients. Therefore, we conducted this retrospective study, attempting to investigate the correlations of preoperative NRS-2002, CNP and SIS with their prognostic impacts on progression-free survival (PFS) and OS in ESCC patients.

Materials and methods

Patients

Between January 2010 and December 2013, a total of 277 esophageal carcinoma patients who underwent esophagectomy and lymph node dissections at the Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, were recruited in this retrospective research. The inclusion criteria were as follows: 1) curative esophagectomy with R0 resection and no presence of preoperative adjuvant therapy; 2) histologically proven ESCC; 3) normal liver and renal function, without severe dysfunction of important organs, and overall performance status of 0 or 1; 4) complete record of pretreatment hematological variables; 5) no presence of distant metastasis; 6) without second primary cancers before or at diagnosis; 7) patients with complete follow-up time; and 8) no presence of infection or inflammatory conditions, such as rheumatologic conditions, connective tissue disorders or heart diseases. Finally, 277 patients were enrolled and analyzed in this study. Clinicopathological features were obtained from the patients’ medical records. The hematological and laboratory parameters were routinely examined in all patients within 1 or 2 weeks prior to surgery. All patients were staged according to the American Joint Committee on Cancer staging manual (seventh edition, 2010). This research was approved by the Ethics Committee of The First Affiliated Hospital of Soochow University. Informed written consent was obtained from all individual participants included in this study.

Surgery

Esophagectomy with thoracic and abdominal dissection was required in each surgical procedure, including the left thoracotomy with standard lymphadenectomy and the cervico-thoraco-abdominal approach with extended lymphadenectomy. In this research, 168 patients (61%) underwent two-field lymphadenectomy. In this cohort of patients, thoracoabdominal lymphadenectomy was performed, including the subcarinal, paraesophageal, pulmonary ligament, diaphragmatic and pericardial lymph nodes, as well as those located along the lesser gastric curvature, the origin of the left gastric artery, the celiac trunk, the common hepatic artery and the splenic artery. For 109 (39%) patients, the three-field lymphadenectomy was performed, and in this group, the cervical lymph nodes were thought to be abnormal according to preoperative imaging evaluation.

Nutritional assessment

Nutritional risk was assessed by NRS-2002 within 1 week before surgery. NRS-2002 consists of impaired nutritional status (low, moderate or severe) and severity of disease (low,
moderate or severe), with an adjustment for age ≥70 years. Nutritional status was evaluated by three variables: body mass index (BMI), recent weight loss and food intake during 1 week before treatment. For severity of disease, as an indicator of stress metabolism and increased nutritional requirements, a score between 1 and 3 was given according to the recommendations. A data collection sheet was used to obtain information about changes in the body weight, food intake and severity of disease according to the ESPEN guidelines. A total score exceeding 3 suggested nutritional risk, whereas that below 3 suggested no nutritional risk temporarily.

Hematological parameters calculation and follow-up

The following pretreatment hematological parameters were collected within 1 week prior to the initial treatment: serum albumin, neutrophil count, lymphocyte count, monocyte count and platelet count. NLR, PLR and LMR were calculated by division of the absolute values of the corresponding hematological parameters. The median values of serum albumin, NLR, PLR and LMR were as the optimum cutoff value. Then the SIS was scored as follows: patients with both elevated serum albumin and elevated LMR were assigned a score of 0, patients with either decreased serum albumin or decreased LMR were assigned a score of 1 and patients with both decreased serum albumin and decreased LMR were assigned a score of 2. Correspondingly, the CNP was established based on the combination of NLR and PLR: patients with both an elevated NLR and PLR were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.

After the completion of treatment, all patients were asked to return to the hospital for examination every 3 months for the first year, every 6 months for the next 2 years and then annually. The duration of follow-up was calculated from the day of treatment to the day of death or March 2018.

Statistical analysis

Statistical analysis was performed with the Statistical Package for Social Science program (SPSS for Windows, version 17.0, SPSS Inc., Chicago, IL, USA). CNP and SIS were divided into CNP 0, SIS 0 and CNP1/2, SIS 1/2 groups by corresponding score, respectively. The relationships between clinical characteristics and CNP, SIS and NRS-2002 were examined by chi-square test or Fisher’s exact test. The end points for this study were 5-year PFS and 5-year OS. PFS was defined as the length of time after surgery during which the patient survived with no sign of tumor recurrence. OS was calculated from date of surgery to the date of individual’s death or last follow-up. The Kaplan–Meier method and log-rank tests were used for 5-year PFS and 5-year OS analyses. Univariate and multivariate analyses of Cox regression proportional hazard model were used to evaluate the influence of each variable on PFS and OS with the enter method. Hazard ratio (HR) with 95% confidence interval (CI) was used to quantify the strength of the association between predictors and survival. Receiver operating characteristic (ROC) curves were also plotted to verify the accuracy of CNP, SIS and NRS-2002 for survival prediction. A 2-tailed P-value ≤0.05 was considered statistically significant.

Results

Clinicopathological characteristics of patients

The basic characteristics of the enrolled patients are shown in Table 1. Among the 277 patients, 62 (22%) were females and 215 (78%) were males. The median age prior to surgery was 62 years (range 40–82 years). The location of the tumors mostly occurred in the middle third (179/277, 65%) and the lower third (88/277, 31%) of the esophagus. In our cohort, 109 (39%) patients underwent esophagectomy alone and 168 (61%) received postoperative chemotherapy or radiotherapy. None of these patients received neoadjuvant therapy before surgery. The median follow-up period was 36 months (range 6–72 months). During the follow-up period, 223 (80%) patients had tumor recurrences (48 cases with surgical anastomosis recurrences, 118 cases with locally regional lymph node metastasis and 57 cases with distant metastasis).

Associations of NRS-2002 and inflammation-based markers with clinicopathological characteristics

The relationships of CNP, SIS and NRS-2002 with clinicopathological characteristics are shown in Table 2. We determined the cutoff value of 42.20 g/L for serum albumin, 3.01 for NLR, 133.33 for PLR and 3.66 for LMR according to the corresponding median values. As already mentioned, the CNP was established based on the combination of NLR and PLR and the SIS was established based on the combination of serum albumin and LMR; then, 100 (36%) and 77 (28%) patients were assigned a score of 0 in CNP and SIS, respectively; 74 (27%) and 119 (43%) patients were assigned a score of 1 in CNP and SIS, respectively; and 103 (37%) and 81 (29%) patients were assigned a score of 2 in CNP and SIS, respectively.

As shown in Table 2, we identified a close relationship between CNP, SIS, NRS-2002 and TNM stage (all P<0.05).
that is to say, high CNP, SIS and NRS-2002 score, compared with low ones, were significantly correlated with advanced TNM staging. Furthermore, we found that the high scores in SIS and CNP were significantly correlated with more advanced N status ($P<0.05$). In addition, the NRS-2002 $\geq 3.0$ group was related to advanced T stage and elder age.

**PFS and OS according to CNP, SIS and NRS-2002 status**

Among the 227 patients, the median PFS time was 15 months (range: 2–72 months); the PFS rates at the 1-, 3- and 5-year period were 59.6%, 22.0% and 19.5%, respectively; as shown in Figure 1, in the CNP=0 group, the 1-, 3- and 5-year PFS rates were 80.0%, 45.0% and 42.0%, respectively; in the CNP=1 group, the PFS rates were 52.7%, 12.2% and 12.2%, respectively; and in the CNP=2 group, the PFS rates were 49.4%, 12.3% and 9.9%, respectively (Figure 1A; $\chi^2=60.348, P=0.000$). In the SIS=0 group, the 1-, 3- and 5-year PFS rates were 75.3%, 39.0% and 33.8%, respectively; in the SIS=1 group, the PFS rates were 56.3%, 17.6% and 16.8%, respectively; and in the SIS=2 group, the PFS rates were 49.4%, 12.3% and 9.9%, respectively (Figure 1B; $\chi^2=19.057, P=0.000$). In the NRS-2002 $<3.0$ group, the 1-, 3- and 5-year PFS rates were 65.8%, 37.3% and 33.5%, respectively, while in the SIS-2002 $\geq 3.0$ group, the PFS rates were 50.9%, 5.20% and 0.00%, respectively (Figure 1C; $\chi^2=48.702, P=0.000$).

Correspondingly, in our cohort, the median OS time was 36 months (range: 6–72 months); the OS rates at the 1-, 3- and 5-year time were 96.4%, 47.7% and 29.6%, respectively; the OS grouped according to CNP, SIS and NRS-2002 status. Additionally, the 1-, 3, and 5-year OS rates were 99.0%, 70.0% and 56.0% in the CNP=0 group, 95.9%, 43.2% and 25.7% in the CNP=1 group, and 94.2%, 29.1% and 6.8% in the CNP=2 group, separately (Figure 2A; $\chi^2=83.427, P=0.000$). The 1-, 3, and 5-year OS rates were 92.2%, 25.9% and 2.6% in the CNP=0 group, 95.8%, 47.1% and 26.1% in the SIS=0 group, 95.2%, 30.9% and 12.2% in the SIS=1 group, and 93.8%, 30.9% and 12.3% in the SIS=2 group (Figure 2B; $\chi^2=36.552, P=0.000$), respectively. Furthermore, in the NRS-2002 $<3.0$ group, the 1-, 3- and 5-year OS rates were 98.8%, 63.4% and 49.1% separately, while in the NRS-2002 $\geq 3.0$ group, the OS rates were 92.2%, 25.9% and 2.6% respectively (Figure 2C; $\chi^2=83.427, P=0.000$). On a whole, PFS and OS of patients in the CNP=0, SIS=0 and NRS-2002 $<3.0$ group were obviously improved compared with patients in the CNP=1/2, SIS=1/2 and NRS-2002 $\geq 3.0$ groups.

**Univariate and multivariate survival analyses**

The results of univariate analysis of the factors related to PFS and OS are shown in Table 3. In univariate analysis, the

### Table 1 Clinicopathological characteristics of 277 patients with esophageal squamous cell carcinoma following surgery

| Characteristic       | Patients, n (%) |
|----------------------|-----------------|
| **Sex**              |                 |
| Male                 | 215 (78)        |
| Female               | 62 (22)         |
| **Age (years)**      |                 |
| Mean±SD             | 62.5±0.44       |
| Median (range)       | 62.00 (40–82)   |
| **Tumor location**   |                 |
| Upper                | 10 (4)          |
| Middle               | 179 (65)        |
| Lower                | 88 (31)         |
| **Differential grade**|               |
| Well                 | 18 (6)          |
| Moderate             | 182 (66)        |
| Poor                 | 77 (28)         |
| **T classification** |                 |
| T1                   | 20 (7)          |
| T2                   | 92 (33)         |
| T3                   | 153 (55)        |
| T4                   | 12 (5)          |
| **N classification** |                 |
| N0                   | 142 (51)        |
| N1                   | 82 (30)         |
| N2                   | 53 (19)         |
| **TNM stage**        |                 |
| I                    | 16 (6)          |
| II                   | 125 (45)        |
| III                  | 134 (48)        |
| IV                   | 2 (1)           |
| **Adjuvant therapy** |                 |
| No                   | 109 (39)        |
| Yes                  | 168 (61)        |
| **Recurrence**       |                 |
| No                   | 54 (20)         |
| Yes                  | 223 (80)        |
| **NLR**              |                 |
| Mean±SD             | 3.25±0.14       |
| Median (range)       | 3.01 (0.73–23.56) |
| **PLR**              |                 |
| Mean±SD             | 147.36±3.76     |
| Median (range)       | 133.33 (22.26–428.0) |
| **LMR**              |                 |
| Mean±SD             | 3.88±0.12       |
| Median (range)       | 3.66 (0.55–12.86) |
| **Albumin (g/L)**    |                 |
| Mean±SD             | 42.04±0.27      |
| Median (range)       | 42.20 (31–75)   |
| **NRS-2002**         |                 |
| Mean±SD             | 2.13±0.07       |
| Median (range)       | 2.0 (1–5.0)     |
| **CNP score**        |                 |
| 0                    | 100 (36)        |
| 1                    | 74 (27)         |
| 2                    | 103 (37)        |
| **SIS score**        |                 |
| 0                    | 77 (28)         |
| 1                    | 119 (43)        |
| 2                    | 81 (29)         |

**Abbreviations:** T, tumor; N, lymph node; TNM, tumor-node-metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; NRS-2002, Nutritional Risk Screening 2002; CNP, combination of NLR and PLR; SIS, systemic inflammation score.
Pretreatment NRS-2002 score and hematologic inflammation markers in ESCC

The following factors were significantly associated with poor PFS and OS: sex, T stage, N stage, TNM stage, CNP, SIS and NRS-2002 (all \( p < 0.05 \)). Table 4 shows the results of multivariate Cox regression analysis of the factors related to PFS and OS. This analysis showed that CNP (HR=1.602; 95% CI 1.341–1.913; \( P=0.000 \)), NRS-2002 (HR=2.062; 95% CI 1.523–2.792; \( P=0.000 \)) and TNM stage (HR=1.194; 95% CI 1.058–1.565; \( P=0.048 \)) were independent prognostic factors for PFS in patients with ESCC after surgery. Correspondingly, CNP (HR=1.707; 95% CI 1.405–2.074; \( P=0.000 \)), NRS-2002 (HR=2.716; 95% CI 1.972–3.740; \( P=0.000 \)) and TNM stage (HR=2.363; 95% CI 1.086–1.691; \( P=0.036 \)) were also independent prognostic factors for OS in ESCC patients following surgery (Table 4).

**Table 2 Characteristics of 277 ESCC patients stratified by CNP, SIS and NRS-2002 scores**

| Factors          | CNP 0 (n=100) | CNP 1 (n=74) | CNP 2 (n=103) | P-value | SIS 0 (n=77) | SIS 1 (n=119) | SIS 2 (n=81) | P-value | NRS-2002 3.0 (n=116) | NRS-2002 <3.0 (n=161) | P-value |
|------------------|---------------|--------------|---------------|---------|--------------|--------------|--------------|---------|----------------------|----------------------|---------|
| Sex              |               |              |               |         |              |              |              |         |                      |                      |         |
| Male             | 74            | 54           | 87            | 0.108   | 47           | 99           | 69           | 0.000   | 89                   | 126                   | 0.762   |
| Female           | 26            | 20           | 16            |         | 30           | 20           | 12           |         | 27                   | 35                    |         |
| Age (years)      |               |              |               |         |              |              |              |         |                      |                      |         |
| <62              | 39            | 26           | 50            | 0.166   | 32           | 50           | 33           | 0.984   | 39                   | 76                    | 0.024   |
| ≥62              | 61            | 48           | 53            |         | 45           | 69           | 48           |         | 77                   | 85                    |         |
| Location         |               |              |               |         |              |              |              |         |                      |                      |         |
| Upper+middle     | 71            | 59           | 59            | 0.005   | 62           | 77           | 50           | 0.022   | 72                   | 117                   | 0.062   |
| Lower            | 29            | 15           | 44            |         | 15           | 42           | 31           |         | 44                   | 44                    |         |
| T stage          |               |              |               |         |              |              |              |         |                      |                      |         |
| T1+T2            | 44            | 34           | 34            | 0.148   | 39           | 47           | 26           | 0.057   | 32                   | 80                    | 0.000   |
| T3+T4            | 56            | 40           | 69            |         | 38           | 72           | 55           |         | 84                   | 81                    |         |
| N stage          |               |              |               |         |              |              |              |         |                      |                      |         |
| N0               | 61            | 35           | 46            | 0.048   | 48           | 61           | 33           | 0.025   | 55                   | 87                    | 0.277   |
| N1+N2            | 39            | 39           | 57            |         | 29           | 58           | 48           |         | 61                   | 74                    |         |
| TNM stage        |               |              |               |         |              |              |              |         |                      |                      |         |
| I+II             | 62            | 35           | 44            | 0.018   | 50           | 56           | 35           | 0.013   | 53                   | 88                    | 0.041   |
| III+IV           | 38            | 39           | 59            |         | 27           | 63           | 46           |         | 63                   | 73                    |         |

Abbreviations: ESCC, esophageal squamous cell carcinoma; CNP, combination of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio; SIS, systemic inflammation score; NRS-2002, Nutritional Risk Screening 2002; T, tumor; N, lymph node; TNM, tumor-node-metastasis.

**Table 3 Univariate analysis of survival of esophageal squamous cell carcinoma treated by surgery**

| Factors                                      | Progression-free survival | Overall survival |
|----------------------------------------------|---------------------------|-----------------|
|                                              | HR 95% CI                  | P-value         | HR 95% CI                  | P-value         |
| Age (≥62 versus <62 years)                   | 0.813 0.624–1.061          | 0.128           | 1.023 0.769–1.361          | 0.874           |
| Sex (female versus male)                     | 1.386 1.061–3.601          | 0.042           | 1.441 1.007–2.063          | 0.046           |
| Location (upper+middle versus lower)         | 1.170 0.885–1.548          | 0.271           | 1.277 0.951–1.715          | 0.104           |
| Differential grade (poor versus well+moderate)| 0.882 0.692–1.123          | 0.308           | 0.818 0.628–1.066          | 0.138           |
| T stage (T1+T2 versus T3+T4)                 | 1.300 1.140–3.308          | 0.035           | 1.933 1.432–2.611          | 0.015           |
| N stage (N0 versus N1+N2)                    | 1.369 1.053–1.781          | 0.019           | 1.479 1.129–1.984          | 0.005           |
| TNM stage (I+II versus III+IV)               | 1.374 1.056–1.788          | 0.018           | 1.582 1.193–2.099          | 0.001           |
| CNP (0 versus 1–2)                           | 1.797 1.534–2.105          | 0.000           | 2.052 1.723–2.443          | 0.000           |
| SIS (0 versus 1–2)                           | 1.449 1.218–1.725          | 0.003           | 1.775 1.464–2.153          | 0.005           |
| NRS-2002 (<3.0 versus ≥3.0)                  | 2.516 1.910–3.314          | 0.000           | 3.641 2.700–4.910          | 0.000           |

Abbreviations: HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis; CNP, combination of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio; SIS, systemic inflammation score; NRS-2002, Nutritional Risk Screening 2002.

**ROC curve for survival prediction**

Figure 3 shows the ROC curves analysis of CNP, SIS and NRS-2002 for PFS and OS prediction. As shown in Figure 3A, the area under the curve (AUC) for CNP, SIS and NRS-2002 was 0.788 (95% CI: 0.727–0.850, \( P=0.000 \)), 0.654 (95% CI: 0.573–0.736, \( P=0.003 \)) and 0.760 (95% CI: 0.704–0.816, \( P=0.000 \)), respectively. The results indicated that CNP and
Figure 1 Kaplan–Meier survival curves for progression-free survival (PFS) in patients with esophageal squamous cell carcinoma (ESCC) after surgery. (A) 1-, 3- and 5-year PFS of patients with combination of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (CNP)=0 were longer than those with CNP=1 or 2. (P=0.000, log-rank). (B) 1-, 3- and 5-year PFS of patients with systemic inflammation score (SIS)=0 were obviously different from those with SIS=1 or 2. (P=0.000, log-rank). (C) 1-, 3- and 5-year PFS of patients with Nutritional Risk Screening 2002 (NRS-2002)<3 were obviously improved compared with patients in NRS-2002 ≥3. (P=0.000, log-rank).

Table 4 Multivariate analysis of survival of esophageal squamous cell carcinoma treated by surgery

| Factors      | Progression-free survival | Overall survival |
|--------------|---------------------------|------------------|
|              | HR                        | 95% CI           | P-value | HR                        | 95% CI           | P-value |
| Sex          | 1.257                     | 0.894–1.768      | 0.188   | 1.122                     | 0.772–1.629      | 0.547   |
| TNM stage    | 1.194                     | 1.058–1.565      | 0.048   | 1.363                     | 1.086–1.691      | 0.036   |
| CNP          | 1.602                     | 1.341–1.913      | 0.000   | 1.707                     | 1.405–2.704      | 0.000   |
| SIS          | 0.966                     | 0.786–1.188      | 0.745   | 1.133                     | 0.903–1.421      | 0.281   |
| NRS-2002     | 2.062                     | 1.523–2.792      | 0.000   | 2.716                     | 1.972–3.740      | 0.000   |

Abbreviations: HR, hazard ratio; CI, confidence interval; T, tumor; N, lymph node; TNM, tumor-node-metastasis; CNP, combination of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio; SIS, systemic inflammation score; NRS-2002, Nutritional Risk Screening 2002.
NRS-2002 were superior to SIS as predictive factors for PFS in patients with ESCC receiving surgery.

ROC curves for OS were also plotted; as shown in Figure 3B, AUC was 0.774 (95% CI: 0.715–0.832, \( P=0.000 \)) for CNP, 0.699 (95% CI: 0.632–0.766, \( P=0.045 \)) for SIS and 0.771 (95% CI: 0.717–0.826, \( P=0.000 \)) for NRS-2002, indicating that CNP and NRS-2002 were also superior to SIS as predictive factors for OS in patients with ESCC after surgery.

### Discussion

Malnutrition and systemic inflammatory response are common in various malignancies and are correlated with poor prognosis. In this clinical research, we explored the importance for the survival prediction of pretreatment NRS-2002, CNP and SIS scores in patients with ESCC receiving surgery. The present study demonstrated that CNP and NRS-2002 were not only the significant risk factors for PFS, but also the independent prognostic factors for OS in ESCC patients following surgery. To the best of our knowledge, this is the first report to demonstrate the clinical significance of CNP and SIS combined with NRS-2002 in patients with ESCC by curative surgery.

Malnutrition has been considered as a significant prognostic factor in cancer patients since 1980, when Dewys et al\(^\text{25}\)
discovered a shorter survival in malnourished patients compared with well-nourished ones. Since then, the correlation between nutritional risk and clinical prognosis has also been demonstrated in a variety of patients, including different types of malignancies.26 Liu et al27 demonstrated that preoperative nutritional status, a novel nutritional-based prognostic score, was independently associated with OS in gastric cancer. Wu et al6 showed that pre-therapeutic serum albumin level was a significant prognostic factor for survival outcomes in patients who underwent esophagectomy. Therefore, nutritional assessment is critical to the efficacy and prognosis of anti-neoplastic therapy, and it should be taken into consideration along with other well-defined prognostic factors for better preoperative assessment and prognostic evaluation.

At present, there are many assessment methods applied to nutritional evaluation; among these, patient-generated subjective global assessment (PG-SGA) is widely used as a golden standard for subjective assessment of nutritional status in cancer patients.28–29 On the other hand, NRS-2002 is a valid method for identifying risk patients and those who will benefit from nutritional treatment.11 A previous study has shown that 28% of patients were at nutritional risk based on NRS-2002, and 34% of patients with head and neck cancer were malnourished according to PG-SGA.30 These results suggested that NRS-2002 seems to be a reliable indicator of malnutrition. Because PG-SGA required specialized nurses to implement and needed long-time evaluation in everyday clinical practice, in contrast, NRS-2002 was the first one developed via evidence-based medicine in the world, with a great advantage of the prediction of malnutrition risk, and it was applicable for a preoperative assessment for patients with ESCC receiving surgery, with the characteristics of non-invasiveness, objective evaluation, convenience and generalization. Therefore, our present study cohort adopts NRS-2002 as nutritional risk assessment tool to stratify patients in malnourished and well-nourished groups. The results showed that PFS and OS of ESCC patients in the NRS-2002 <3.0 group were obviously improved compared with those of patients in the NRS-2002 ≥3 groups. These results indicated that NRS-2002 might be an excellent instrument in predicting the association between nutritional risk and clinical outcome; consequently, preoperative nutritional support is necessary in ESCC patients with a preoperative nutritional score (NRS-2002) ≥3.0.

In the case of hematologic inflammation markers, a high CNP score was significantly associated with poor PFS and OS in our ESCC patients receiving curative esophagectomy with R0 resection. Since the pathologist Rudolf Virchow first discovered leukocytes in malignant tissue specimens about 150 years ago,31 the prognostic values of pretreatment hematologic markers have been highlighted. Compelling evidence suggested that there were statistically significant differences in the survival rates grouped by NLR, PLR and LMR levels for several types of malignancies.16–19 However, the current study also showed that hematologic parameters were controversial in the prediction of prognosis in esophage carcinoma. Duan et al32 reported that preoperative serum NLR is a useful prognostic marker to complement TNM staging.
for operable ESCC patients, particularly in patients with stage IIIA disease; on the contrary, Rashid et al.\textsuperscript{13} found that NLR did not prove to be a significant predictor of number of involved lymph nodes, disease recurrence or death. Furthermore, survival time was not significantly different between patients with high ($\geq 3.5$) or low ($<3.5$) NLR ($P=0.49$). This controversy might result from the optimal cutoff points for NLR and PLR to predict overall survival. In our present study, therefore, the median values of NLR and PLR were as the cutoff point, which were 3.01 and 133.33, respectively, and then the CNP score was established based on the combination of NLR and PLR, consisting of more prognostic information than single NLR or PLR; the results indicated that pretreatment CNP score was an independent risk factor for PFS and OS in ESCC following surgery; nevertheless, there was no prognostic association found for SIS in multivariate analyses.

The limitations of this study are as follows: first, not all hematologic markers of inflammation were used in the analysis, because some biomarkers were not routinely examined, such as C-reactive protein\textsuperscript{34} and fibrinogen.\textsuperscript{35} Second, it was a single-institution, retrospective study. Third, relying on recalled weight, height and food intake from the medical record might have caused bias in assessing BMI and weight change, and ultimately had some effect on NRS-2002 rating; finally, 277 patients with ESCC were enrolled in this study and the sample size is relatively small and may be insufficient to strengthen our results. Given these limitations, future larger randomized trials are needed to clarify these results.

In conclusion, this study demonstrated that CNP combined with NRS-2002 is promising as a predictive marker for predicting clinical outcomes in patients with ESCC receiving surgery. However, considering the retrospective nature of this study, large-scaled prospective trials are still warranted to verify our results.

**Acknowledgment**

This work was supported by the grant from Suzhou Cancer Clinical Medical Center (grant no. Szxx201506).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
2. Chen WQ, He YT, Zheng RS, et al. Esophageal cancer incidence and mortality in China, 2009. *J Thorac Dis*. 2013;5(1):19–26.
3. Vizzaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. *Int J Cancer*. 2002;99(6):860–868.
4. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. *Lancet*. 2013;381(9864):400–412.
5. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? *Eur J Cardiothorac Surg*. 2012;41(3):e7–e11.
6. Wu N, Chen G, Hu H, Pang L, Chen Z. Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas. *Nutr Cancer*. 2015;67(3):481–485.
7. Watanabe M, Ishimoto T, Baba Y, et al. Prognostic impact of body mass index in patients with squamous cell carcinoma of the esophagus. *Ann Surg Oncol*. 2013;20(12):3984–3991.
8. Yoshida N, Harada K, Baba Y, et al. Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer. *Langenbecks Arch Surg*. 2017;402(2):333–341.
9. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? *J Parenter Enteral Nutr*. 1987;11(1):8–13.
10. Vellas B, Villars H, Abellan G, et al. Overview of the MNA—its history and challenges. *J Nutr Health Aging*. 2006;10(6):456–463; discussion 463–465.
11. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr*. 2003;22(3):321–336.
12. Chen W, Jiang Z, Zhang Y. Evaluation of European nutritional risk screening method in Chinese hospitalized patients practices. *Chin J Clin Nutr*. 2005;13:137–141.
13. Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. *Br J Cancer*. 2012;107(2):275–279.
14. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. *Crit Rev Oncol Hematol*. 2013;88(1):218–230.
15. Schütte K, Tippelt B, Schulz C, et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). *Clin Nutr*. 2015;34(6):1122–1127.
16. Galizia G, Lieto E, Zamboli A, et al. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. *Surgery*. 2015;158(1):112–120.
17. Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet–lymphocyte and neutrophil–lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. *Dis Esopha-gus*. 2016;29(1):79–85.
18. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. *World J Surg Oncol*. 2014;12:58.
19. Han LH, Jia YB, Song QX, Wang JB, Wang NN, Cheng YF. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma. *Asian Pac J Cancer Prev*. 2015;16(6):2245–2250.
20. Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. *Onco Targets Ther*. 2013;6:1605–1612.
21. Han L, Song Q, Jia Y, et al. The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma. *Tumour Biol*. 2016;37(3):3081–3090.
22. Chang Y, An H, Xu L, et al. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. *Br J Cancer*. 2015;113(4):626–633.
23. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. *Ann Surg Oncol*. 2010;17(7):1721–1724.

24. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M; Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. *Clin Nutr*. 2003;22(4):415–421.

25. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med*. 1980;69(4):491–497.

26. Sorensen J, Kondrup J, Prokopowicz J, et al; EuroOOPS Study Group. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. *Clin Nutr*. 2008;27(3):340–349.

27. Liu X, Qiu H, Kong P, Zhou Z, Sun X. Gastric cancer, nutritional status, and outcome. *Onco Targets Ther*. 2017;10:2107–2114.

28. Ottery FD. Definition of standardized nutritional assessment and interventional pathways in oncology. *Nutrition*. 1996;12(Suppl 1):S15–S19.

29. Bauer J, Capra S, Ferguson M. Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. *Eur J Clin Nutr*. 2002;56(8):779–785.

30. Orell-Kotikangas H, Österlund P, Saarilahti K, Ravasco P, Schwab U, Mäkitie AA. NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients. *Support Care Cancer*. 2015;23(6):1495–1502.

31. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*. 2001;357(9255):539–545.

32. Duan H, Zhang X, Wang FX, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. *World J Gastroenterol*. 2015;21(18):5591–5597.

33. Rashid F, Waraich N, Bhatti I, et al. A pre-operative elevated neutrophil-lymphocyte ratio does not predict survival from oesophageal cancer resection. *World J Surg Oncol*. 2010;8:1.

34. Thurner EM, Krenn–Pilko S, Langsenlehner U, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. *Eur J Cancer*. 2015;51(5):610–619.

35. Kijima T, Arigami T, Uchikado Y, et al. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. *Cancer Sci*. 2017;108(2):193–199.